Breast Cancer Association with CYP1A2 Activity and Gene Polymorphisms - a Preliminary Case-control Study in Tunisia

  • Ayari, I (Metabolic Biophysics and Applied Pharmacology Laboratory, Department of Biophysics, Faculty of Medicine, University of Sousse) ;
  • Arnaud, MJ (Nutrition & Biochemistry) ;
  • Mani, A (Metabolic Biophysics and Applied Pharmacology Laboratory, Department of Biophysics, Faculty of Medicine, University of Sousse) ;
  • Pavanello, S (Occupational Health Section, Department of Cardiological, Thoracic and Vascular Sciences, University of Padova) ;
  • Saguem, S (Metabolic Biophysics and Applied Pharmacology Laboratory, Department of Biophysics, Faculty of Medicine, University of Sousse)
  • Published : 2015.04.29


The aim of the present study was to evaluate the relative contribution of CYP1A2 isoforms (-3860 G/A, -2467T/delT and -163C/A) in control subjects and breast cancer patients to the metabolism of caffeine in human liver. Restriction fragment length polymorphism analysis of PCR-amplified Fragments (PCR-RFLP) was used for the genotyping of CYP1A2 SNPs and HPLC allowed the phenotyping through the measurement of CYP1A2 activity using the 17X + 13X + 37X/137X urinary metabolite ratio (CMR) and plasma caffeine half life (T1/2). The CYP1A2 -3860A genotype was associated with a decreased risk of breast cancer. In contrast, distributions of the CYP1A2 -2467T/delT or -2467delT/delT and -163A/C or A/A genotypes among breast cancer patients and controls were similar. When the genotype and phenotype relationship was measured by comparing the mean CMR ratios and caffeine half life within the genotype groups between subjects and breast cancer patients, there were no significant differences except for -3860 A, most of them being homozygous for the -3860 G/G SNP and had a significant higher mean CMR ratio and half life than those with -3860 G/A (P=0.02). The results of this preliminary study show a significant association between CP1A2 -3860 G variant and CYP1A2 phenotype which must be confirmed by further large-size case-control studies.


Breast cancer;CYP1A2;gene polymorphism;phenotype


  1. Agundez JA (2004). Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab, 5, 211-24.
  2. Ahlbom A, Lichtenstein P, Malmstrom H, et al (1997) Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst, 89, 287-93.
  3. Arnaud MJ (2011). Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol, 200, 33-91.
  4. Bageman E1, Ingvar C, Rose C, Jernstrom H (2008) Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomarkers Prev, 17, 895-901.
  5. Bchir F, Dogui M, Ben Fradj R, Arnaud MJ, Saguem S (2006). Differences in pharmacokinetic and electroencephalographic responses to caffeine in sleep-sensitive and non-sensitive subjects. C R Biol, 329, 512-9.
  6. Callahan MM, Robertson RS, Arnaud MJ, et al (1982). Human metabolism of [$1-Methyl-^{14C}$] and [$2-^{14C}$] caffeine after oral administration, Drug Metabolism Disposition, 4, 417-23.
  7. Caubet MS, Elbast W, Dubuc MC, Brazier JL (2002). Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolic ratios to assess CYP1A2 enzyme activity. J Pharm Biomed Anal, 27, 261-70.
  8. Chang-Claude J, Beckmann L, Corson C, et al ; MARIEGENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2010). Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat, 119, 463-74.
  9. DeBruin LS, Josephy PD (2002). Perspectives on the chemical etiology of breast cancer. Environ Health Perspect, 110, 119-28.
  10. Djordjevic N, Ghotbi R, Jankovic S, Aklillu E (2010) Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. Eur J Clin Pharmacol, 66, 697-703.
  11. Evans MD, Butler JM, Nicoll K, Cooke MS, Lunec J (2003). 17 beta-Oestradiol attenuates nucleotide excision repair. FEBS Lett, 535, 153-8.
  12. Grant DM, Tang BK, Kalow W (1984). A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol, 17, 43-50.
  13. Hein DW, Doll MA, Fretland AJ, et al (2000). Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev, 9, 29-42.
  14. Hong C, Tang BK, Hammond GL, et al (2004). Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res, 6, R352-65.
  15. Khvostova EP, Pustylnyak VO, Gulyaeva LF (2012). Genetic polymorphism of estrogen metabolizing enzymes in Siberian women with breast cancer. Genet Test Mol Biomarkers, 16, 167-73.
  16. Kotsopoulos J, Ghadirian P, El-Sohemy A, et al (2007). The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev, 16, 912-6.
  17. Lee HJ, Wu K, Cox DG, et al (2013). Polymorphisms in xenobiotic metabolizing genes, intakes of heterocyclic amines and red meat, and postmenopausal breast cancer. Nutr Cancer, 65, 1122-31.
  18. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR (2005). Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev, 14, 1998-2003.
  19. Long JR, Cai Q, Shu XO, et al (2007). Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. Pharmacogenet Genomics, 17, 331-8.
  20. Long JR, Egan KM, Dunning L, et al (2006) Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics, 16, 237-43.
  21. Lichtenstein P, Holm NV, Verkasalo PK, et al (2000) Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85.
  22. MacLeod SL, Nowell S, Massengill J, et al (2000). Cancer therapy and polymorphisms of cytochromes P450. Clin Chem Lab Med, 38, 883-7.
  23. Missaoui N, Landolsi H, Jaidaine L, et al (2012). Breast cancer in central Tunisia: an earlier age at diagnosis and incidence increase over a 15-year period. Breast J, 18, 289-91.
  24. Missaoui N, Trabelsi A, Parkin DM, et al (2010) Trends in the incidence of cancer in the Sousse region, Tunisia, 1993-2006. Int J Cancer, 127, 2669-77.
  25. Mrizak D, B'chir F, Jaidane M, Arnaud MJ, Saguem S (2011). Effects of changes in smoking habits on bladder cancer incidence in Tunisia. Health, 3, 613-9.
  26. Nakajima M, Yokoi T, Mizutani M, et al (1999). Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem, 125, 803-8.
  27. Qiu LX, Yao L, Mao C, et al (2010). Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects. Breast Cancer Res Treat, 122, 521-5.
  28. Rebbeck TR, Troxel AB, Walker AH, et al (2007). Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev, 16, 444-50.
  29. Sangrajrang S, Sato Y, Sakamoto H, et al (2009). Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer, 125, 837-43.
  30. Shimada N, Iwasaki M, Kasuga Y, et al (2009). Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet, 54, 209-15.
  31. Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP (2011). Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers, 15, 343-9.
  32. Tanaka E, Ishikawa A, Yamamoto Y, et al (1992). A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. Int J Clin Pharmacol Ther Toxicol, 30, 336-41.
  33. Tian Z, Li YL, Zhao L, Zhang CL (2013). Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies. Gene, 524, 168-74.
  34. Turesky RJ (2004). The role of genetic polymorphisms in metabolism of carcinogenic heterocyclic aromatic amines. Current Drug Metabolism, 5, 169-80
  35. van Schaik RH (2008). CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resistance Updates, 11, 77-98.
  36. Williams JA, Phillips DH (2000). Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res, 60, 4667-77.
  37. Zheng W, Gustafson DR, Sinha R, et al (1998). Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst, 90, 1724-9.
  38. Zhenzhen L, Xianghua L, Ning S, et al (2013). Current evidence on the relationship between three polymorphisms in the CYP1A2 gene and the risk of cancer. Eur J Cancer Prev, 22, 607-19.